Spruce Biosciences, Inc. (SPRB) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Price to Book (PBV) Ratio Undervalued price-to-book. SPRB stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) SPRB equity is higher than it's debt.

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth SPRB has never had growing revenue.
Net Income Growth SPRB has never had growing net income.
Net Income SPRB never has positive net income for 2 years.
Dividend Yield SPRB has low dividend yield (0%).
Return of Assets SPRB has low return of asset (-46.4%).
Return of Equity SPRB has low return of equity (-46.64%).
Revenue SPRB never has positive revenue for 2 years.
Return of Invested Capital SPRB has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-35,970,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Mr. Michael G. Grey

Management

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Additional Information

Company name

Spruce Biosciences, Inc.

Symbol

NASDAQ:SPRB

Exchange

NASDAQ Global Select

Industry

Biotechnology

Sector

Healthcare

Address

2001 Junipero Serra Boulevard
Daly City
CA
US
94014

Website

https://www.sprucebiosciences.com